Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...

Musk revealed using Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, highlighting their popularity for weight management.

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

Eli Lilly and Company LLY announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating ...